Phase 2 trial results presented at ASCO showed responses to anti–PD-1 antibody pembrolizumab (Keytruda) in about 60% of colorectal cancers with MMR deficiency, but no responses in CRC lacking this feature. Link is below for those interested. Exciting result for that small subset of patients, which is only 4% of metastatic CRC. SIRT unlikely to be replaced by this expensive new therapy, I don't see why they couldn't be used together in the MMR deficient group.
http://www.ascopost.com/ViewNews.aspx?nid=27670
- Forums
- ASX - By Stock
- SRX
- Immunotherapy
Immunotherapy, page-4
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
NEWS
Antler Copper Project hits major permitting milestone – air quality permit advances to final review